Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ANAPRINT

Financiado

Cerrado

Additive Printing for Cell Based Analysis

The Project shall develop a unique manufacturing solution for the automated production of complex cell models widely used by industry to test biological activity and biosafety. No means of scalable manufacture presently exists. T... ver más

31/10/2018

ACS

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

AvantiCell Science Ltd No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-10-31

NMP-25-2015: Accelerating the uptake of nanotech... Scope:Specific challenge: Research results should be taken up by industry, harvesting the hitherto u...

I+D

Cerrada hace 10 años

0% 70% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

ACS

1.26M€ | Lider

TECNATOM

1.09M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 36 meses Fecha Inicio: 2015-10-11
Fecha Fin: 2018-10-31

Líder del proyecto

AvantiCell Science Ltd No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The Project shall develop a unique manufacturing solution for the automated production of complex cell models widely used by industry to test biological activity and biosafety. No means of scalable manufacture presently exists. The technical solution is to assemble cell models by additive manufacturing; to control the resident cells’ locations within these 3D models; to supply the models to customers as pre-assembled, frozen products. The result shall be an analytical tool which, unlike current practice, does not compromise analytical output for convenience, but combines high predictive value and low cost with exceptional user-friendliness. The solution is unique, proprietary and highly positive-disruptive in its industrial sector. Its achievement will be measurable in this Project as an exemplifying, printed hepatotoxicity assay with wide application in drug discovery and biosafety testing. An SME Instrument Phase 1 Project advanced the core printing technology delivering this solution to TRL7, and developed a business plan for its exploitation. That business plan confirmed the wide, cross-industry application of cell-based analysis, from preclinical drug discovery through natural products/food to medical devices and nanosafety, and mapped the advantages of additively-manufactured products onto demonstrable industry trends and customer needs. The business plan and its underpinning technology are founded in the applicant’s long-term strategic goals, evidenced by profitable business in the target market from proprietary cell-based services, and by ancillary technology developments, also to TRL7 and supported by UK national funding, which create unique competitive advantage. The outcome of this Phase 2 Project will be a mature cell-based manufacturing technology, its demonstrable application in a commercial environment, and the assembly of a corporate infrastructure ready to take the Project’s manufacturing solution into a well-scoped and lucrative marketplace.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores